BioAtla, Inc. filings document the regulatory record for a clinical-stage biotechnology company developing CAB antibody therapeutics for solid tumors. Recent Form 8-K disclosures cover financial results, investor presentation materials, cost-reduction actions, executive retention compensation, financing arrangements, license-related updates and risk-linked operating disclosures.
The filings also record capital-structure and governance matters, including shareholder votes on stock issuance and reverse split authority, Series A Junior Preferred Stock issuance and elimination, Nasdaq continued-listing proceedings, and a Delaware certificate of merger connected to a common-stock reclassification.
BioAtla (BCAB) reported Q3 2025 results, highlighting a continued operating loss and liquidity pressure. The company recorded a quarterly net loss of $15.8 million (net loss per share $0.27) and a year‑to‑date net loss of $49.8 million. There was no collaboration revenue in the quarter, versus $11.0 million a year ago.
Operating expenses fell as programs wound down: R&D was $9.5 million (down from $16.4 million) and G&A was $4.3 million (down from $5.9 million). Cash and cash equivalents were $8.3 million at September 30, 2025, down from $49.0 million at year‑end, and management concluded there is “substantial doubt” about the ability to continue as a going concern.
The balance sheet showed total liabilities of $47.1 million, including a $19.8 million licensor liability and a $4.3 million warrant liability, resulting in stockholders’ deficit of $(31.2) million. Shares outstanding were 58,792,088 as of November 10, 2025. A subsequent event notes receipt of a $2.0 million milestone under the Context license.
BioAtla, Inc. (BCAB) furnished an 8-K announcing its Q3 2025 results and a clinical program update. The company reported that a press release covering the quarter ended September 30, 2025 has been provided as Exhibit 99.1.
The information in Item 2.02, including Exhibit 99.1, is being furnished, not filed, and will not be incorporated by reference into other filings. BioAtla’s common stock trades on The Nasdaq Capital Market under the symbol BCAB.
BioAtla, Inc. reports that a Nasdaq Hearings Panel has granted its request for continued listing, subject to specific conditions and deadlines. The company must apply to transfer its shares to The Nasdaq Capital Market by September 26, 2025, demonstrate compliance with Nasdaq’s minimum stockholders’ equity requirement by December 31, 2025, and meet the minimum bid price requirement by February 2, 2026. BioAtla submitted its application to transfer on September 18, 2025 and believes it can regain compliance with both requirements, though it cautions there is no assurance this will occur. The company also highlights risks including factors that raise substantial doubt about its ability to continue as a going concern and its need for additional funding to continue developing its CAB technology platform and product candidates.
Jay M. Short, Chief Executive Officer, Director and reported 10% owner of BioAtla, Inc. (BCAB), filed a Form 4 disclosing a non-sale transaction on 08/31/2025. The filing shows 6,347 shares of Common Stock were withheld by the issuer at a price of $0.4555 to satisfy income tax and withholding obligations related to the vesting and net settlement of previously reported restricted stock units. After the withholding, the reporting person directly beneficially owned 2,243,678 shares. The Form 4 also reports indirect holdings: 793,547 shares held by spouse, two trusts with 258,727 shares each, 302,324 shares by Capia IP, LLC, and 50 shares by Himalaya Parent LLC, where the reporting person and spouse are managers. The filing was signed by an attorney-in-fact on 09/02/2025.
Christian Vasquez, an officer at BioAtla, Inc. (BCAB) who serves as Chief Accounting Officer, Corporate Controller and Secretary, reported a transaction dated 08/31/2025 in which 1,566 shares of common stock were withheld by the issuer at a price of $0.4555 per share to satisfy income tax and withholding obligations related to the vesting and net settlement of previously reported restricted stock units. The filing shows 283,564 shares beneficially owned following the transaction and is signed by Mr. Vasquez on 09/02/2025. The filer explains this is not a sale but a withholding to cover taxes on vested RSUs.
Eric Sievers, Chief Medical Officer of BioAtla, Inc. (BCAB), reported a withholding transaction tied to vested restricted stock units. On 08/31/2025, 2,729 shares were withheld at an effective price of $0.4555 to satisfy income tax and withholding obligations related to prior RSU vesting. After the withholding, the filing shows 364,574 shares beneficially owned by Sievers. The Form 4 was signed by an attorney-in-fact on 09/02/2025. The filing explicitly states this was a net settlement withholding, not an open-market sale.
Richard A. Waldron, Chief Financial Officer of BioAtla, Inc. (BCAB), reported a transaction dated 08/31/2025 in which 2,371 shares of common stock were disposed of under code F(1) at a price of $0.4555 per share. The filing states these shares were withheld by the issuer to satisfy income tax withholding and remittance obligations related to the vesting and net settlement of previously reported restricted stock units. Following the withholding, the reporting person beneficially owns 338,521 shares (direct ownership). The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 09/02/2025.
BioAtla, Inc. (Nasdaq: BCAB) filed a Form 8-K covering two routine corporate matters: approval of its 2025 Corporate Bonus Plan and the final results of its 2025 Annual Meeting of Stockholders.
2025 Corporate Bonus Plan (Item 5.02): On 17 June 2025 the Board’s Compensation Committee adopted a cash-based incentive plan for the Chief Executive Officer, Chief Financial Officer and Chief Medical Officer. Payouts are driven by four weighted corporate performance goals—clinical development milestones (25%), financing objectives (50%), financial & people objectives (20%), and brand awareness (5%). A minimum threshold of 50 % aggregate achievement is required for any payout; actual bonuses may range from 50 % to 125 % of the executive’s target opportunity. Target bonuses are set as a percentage of base salary: 60 % for CEO Jay Short and 40 % for both CFO Richard Waldron and CMO Eric Sievers.
Annual Meeting results (Item 5.07): Held virtually on 18 June 2025, the meeting reached a quorum with 30,358,471 shares (≈52 % of shares outstanding) represented. Shareholders re-elected three Class II directors for three-year terms, with Lawrence Steinman, M.D. receiving the highest support (11.6 million votes for). Ernst & Young LLP was ratified as independent auditor for FY 2025 (30.2 million votes for; 99.5 % support). A non-binding “say-on-pay” resolution passed with 8.96 million votes in favor versus 4.49 million against.
No other material transactions, earnings data, or strategic changes were disclosed in this filing.